Dry powder drug delivery system
First Claim
Patent Images
1. An inhalation system, comprising:
- a dry powder inhaler comprising;
a mouthpiece and a container, wherein the container comprises a top and a bottom which are moveable relative to one another by a translational motion to create a first flow path, wherein 20% to 70% of total airflow through the inhaler enters and exits the container, and wherein the container includes a dry powder formulation comprising diketopiperazine particles; and
a second flow path wherein 30-80% of total airflow through the inhaler by-passes the container;
wherein the second flow path converges with the first flow path at a substantially perpendicular angle, andwherein after a single inhalation from the inhalation system, diketopiperazine in a subject'"'"'s plasma has an AUC0-∞
greater than 2,300 ng*min/mL per mg of the diketopiperazine content in the dry powder formulation.
4 Assignments
0 Petitions
Accused Products
Abstract
A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation.
-
Citations
20 Claims
-
1. An inhalation system, comprising:
-
a dry powder inhaler comprising; a mouthpiece and a container, wherein the container comprises a top and a bottom which are moveable relative to one another by a translational motion to create a first flow path, wherein 20% to 70% of total airflow through the inhaler enters and exits the container, and wherein the container includes a dry powder formulation comprising diketopiperazine particles; and a second flow path wherein 30-80% of total airflow through the inhaler by-passes the container; wherein the second flow path converges with the first flow path at a substantially perpendicular angle, and wherein after a single inhalation from the inhalation system, diketopiperazine in a subject'"'"'s plasma has an AUC0-∞
greater than 2,300 ng*min/mL per mg of the diketopiperazine content in the dry powder formulation. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
-
19. An inhalation system, comprising:
-
a dry powder inhaler comprising; a mouthpiece and a container, wherein the container includes a dry powder formulation comprising diketopiperazine particles; a first flow path wherein 20% to 70% of total airflow through the inhaler enters and exits the container; and a second flow path wherein 30-80% of total airflow through the inhaler by-passes the container; wherein the first flow path exits the container substantially perpendicularly to the second flow path and is sheared by the second flow path; and wherein after a single inhalation from the inhalation system, diketopiperazine in a subject'"'"'s plasma has an AUC0-∞
greater than 2,300 ng*min/mL per mg of the diketopiperazine content in the dry powder formulation.
-
-
20. An inhalation system, comprising:
-
a dry powder inhaler comprising; a mouthpiece and a container, wherein the container comprises a top and a bottom which are moveable relative to one another by a translational motion, wherein the container includes a dry powder formulation comprising diketopiperazine particles, and wherein the container does not include an air conduit resulting from puncturing or peeling; a first flow path wherein 20% to 70% of total airflow through the inhaler enters and exits the container; and a second flow path wherein 30-80% of total airflow through the inhaler by-passes the container; wherein after a single inhalation from the inhalation system, diketopiperazine in a subject'"'"'s plasma has an AUC0-∞
greater than 2,300 ng*min/mL per mg of the diketopiperazine content in the dry powder formulation.
-
Specification